The journal Clinical Nuclear Medicine has published the results of a study coordinated by the Nuclear Medicine Unit of the Ciudad Real Hospital with the collaboration of MOLAB researchers. The goal was to study the association of metabolic features of 18F-fluorocholine in gliomas with histopathological and molecular parameters, progression-free survival (PFS) and overall survival (OS).
In a prospective multicenter and nonrandomized study patients underwent a basal 18F-fluorocholine PET/CT and were included after histological confirmation of glioma. After tumor segmentation of PET images, SUV and volume-based variables, sphericity, surface, coefficient of variation, and multilesionality were obtained. Relations of metabolic variables with histological, molecular profile and prognosis were evaluated
Significant differences of SUV-based variables with isocitrate dehydrogenase status, tumor grade, and Ki-67 were found. Tumor grade, Ki-67, SUVmax, and SUVmean were related to progression. Kaplan-Meier analysis revealed significant associations of SUVmax, SUVmean, and multilesionaly with OS and PFS. SUVmean, tumor surface regularity, and multilesionality were independent predictors of OS and PFS in Cox regression analysis.
In summary, the study showed that the metabolic information obtained from 18F-fluorocholine PET of patients with glioma may be useful in the prediction of tumor biology and patient prognosis.
18F-Fluorocholine PET/CT in the prediction of molecular subtypes and prognosis for gliomas.
Ana M. Garcia Vicente, Julian Perez-Beteta, Mariano Amo-Salas, Francisco J. Pena Pardo, Maikal Villena, Hernan Sandoval, Manuela Mollejo, Rosa Barbella, Chistoph J. Klein, José M. Borras, Ángel M. Soriano, Víctor M. Pérez-García
Clinical Nuclear Medicine 44(10) e548-e558 (2019).